FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980234003> ?p ?o ?g. }

• W2980234003 abstract "Abstract Title Phase 2 Trial of GS-9973, a selective Syk inhibitor, has Activity in Subjects with Chronic Lymphocytic Leukemia (CLL) Introduction Spleen tyrosine kinase (Syk) is an essential mediator of B-cell receptor signaling in normal and transformed B-cells. GS-9973 is an orally bioavailable, small-molecule, selective inhibitor of Syk. The Kd of GS-9973 for Syk was 7.6 nM with no other kinase < 100 nM (Ambit scanMax at 10 mM). Methods and Subjects This Phase 2 trial enrolled subjects with CLL (1 cohort) or NHL (4 cohorts) of 40 subjects each. All subjects were treated with GS-9973 800 mg BID. Tumor imaging was conducted at weeks 8, 16, 24 and every 12 weeks thereafter. Response was evaluated according to standard criteria for CLL (Hallek 2008 and Cheson 2012). GS-9973 plasma levels were obtained throughout the study and concurrently obtained circulating CD5+CD19+ leukemic cells were assessed for changes in pSyk, pBLNK, pBTK and pAKT expression using a PhosFlow protocol. Chemokine/cytokine plasma levels were assessed using multiplexed bead suspension arrays. Results This study initiated in March 2013. At time of data lock, 56 subjects with CLL/SLL (32) or NHL(24) have been enrolled. 18 subjects with CLL/SLL and 16 subjects with NHL (10 iNHL, 3 DLBCL and 3 MCL) have completed ≥ 4 weeks of treatment and are included in the safety analysis. Median age was 71 (range 55 - 88), 65% were male. The median number of prior treatment regimens was 5 (range 1-14). All CLL/SLL subjects had received an anti-CD20 antibody, 89% had received an alkylating agent (56% had bendamustine) and 72% had received fludarabine. Investigator assessed week 8 efficacy analysis is available for 22/54 patients which included 13 CLL/SLL subjects, 7 of whom had 17p deletions and/or TP53 mutations. At the week 8 evaluation all subjects experienced reduced tumor bulk: 4 subjects achieved a decrease of > 50% in their measurable lymph node disease; 8 had < 50% decrease. One subject with a marked decrease in peripheral lymphadenopathy had unequivocal progression of non-measurable mediastinal disease and was considered to have disease progression. The waterfall plot is provided; the striped bars represent those CLL/SLL subjects with a 17p deletion and/or TP53 mutation. GS-9973 was generally well tolerated. 30 of 34 (88%) of subjects experienced an adverse event. All treatment emergent adverse events occurring in ≥ 10% of 34 subjects are listed in the table. Reversible Grade 3 or 4 transaminase elevations occurred in 4 subjects. Two of the 34 subjects who received at least 1 dose of GS-9973 died while on study: 1 from progressive disease, 1 from pneumonia that occurred after 7 days on study. The absolute lymphocyte count in CLL/SLL subjects increased a mean of 200%, by day 8 and then declined. Decreases in pSyk levels occurred in leukemic cells from 8 of 11 CLL/SLL subjects. The results of the disease-associated chemokines/cytokines assays are pending. Conclusions GS-9973 given on this dose and schedule was generally well tolerated. At the initial 8-week response assessment GS-9973 demonstrated activity in subjects with CLL/SLL, including those with poor prognostic features. Updated data on the larger cohort of CLL/SLL subjects will be presented. Disclosures: Sharman: Gilead Sciences: Research Funding. Hawkins:Gilead Sciences: Employment, Equity Ownership. Hu:Gilead Sciences: Employment, Equity Ownership. Reddy:Gilead Sciences: Employment, Equity Ownership. Jin:Gilead Sciences: Employment, Equity Ownership. Melchor-Khan:Gilead Sciences, Inc.: Employment, Equity Ownership." @default.
• W2980234003 created "2019-10-18" @default.
• W2980234003 creator A5009060912 @default.
• W2980234003 creator A5013007045 @default.
• W2980234003 creator A5023081058 @default.
• W2980234003 creator A5028637128 @default.
• W2980234003 creator A5037264825 @default.
• W2980234003 creator A5051827651 @default.
• W2980234003 creator A5062430369 @default.
• W2980234003 creator A5084091087 @default.
• W2980234003 creator A5085298680 @default.
• W2980234003 creator A5088027886 @default.
• W2980234003 creator A5090935889 @default.
• W2980234003 date "2013-11-15" @default.
• W2980234003 modified "2023-09-27" @default.
• W2980234003 title "Phase 2 Trial Of GS-9973, a Selective Syk Inhibitor, In Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)" @default.
• W2980234003 doi "https://doi.org/10.1182/blood.v122.21.1634.1634" @default.
• W2980234003 hasPublicationYear "2013" @default.
• W2980234003 type Work @default.
• W2980234003 sameAs 2980234003 @default.
• W2980234003 citedByCount "3" @default.
• W2980234003 countsByYear W29802340032014 @default.
• W2980234003 countsByYear W29802340032015 @default.
• W2980234003 countsByYear W29802340032016 @default.
• W2980234003 crossrefType "journal-article" @default.
• W2980234003 hasAuthorship W2980234003A5009060912 @default.
• W2980234003 hasAuthorship W2980234003A5013007045 @default.
• W2980234003 hasAuthorship W2980234003A5023081058 @default.
• W2980234003 hasAuthorship W2980234003A5028637128 @default.
• W2980234003 hasAuthorship W2980234003A5037264825 @default.
• W2980234003 hasAuthorship W2980234003A5051827651 @default.
• W2980234003 hasAuthorship W2980234003A5062430369 @default.
• W2980234003 hasAuthorship W2980234003A5084091087 @default.
• W2980234003 hasAuthorship W2980234003A5085298680 @default.
• W2980234003 hasAuthorship W2980234003A5088027886 @default.
• W2980234003 hasAuthorship W2980234003A5090935889 @default.
• W2980234003 hasConcept C126322002 @default.
• W2980234003 hasConcept C143998085 @default.
• W2980234003 hasConcept C170493617 @default.
• W2980234003 hasConcept C203014093 @default.
• W2980234003 hasConcept C2777938653 @default.
• W2980234003 hasConcept C2778461978 @default.
• W2980234003 hasConcept C2778714382 @default.
• W2980234003 hasConcept C2779260929 @default.
• W2980234003 hasConcept C2779878957 @default.
• W2980234003 hasConcept C35174551 @default.
• W2980234003 hasConcept C42362537 @default.
• W2980234003 hasConcept C71924100 @default.
• W2980234003 hasConcept C90924648 @default.
• W2980234003 hasConceptScore W2980234003C126322002 @default.
• W2980234003 hasConceptScore W2980234003C143998085 @default.
• W2980234003 hasConceptScore W2980234003C170493617 @default.
• W2980234003 hasConceptScore W2980234003C203014093 @default.
• W2980234003 hasConceptScore W2980234003C2777938653 @default.
• W2980234003 hasConceptScore W2980234003C2778461978 @default.
• W2980234003 hasConceptScore W2980234003C2778714382 @default.
• W2980234003 hasConceptScore W2980234003C2779260929 @default.
• W2980234003 hasConceptScore W2980234003C2779878957 @default.
• W2980234003 hasConceptScore W2980234003C35174551 @default.
• W2980234003 hasConceptScore W2980234003C42362537 @default.
• W2980234003 hasConceptScore W2980234003C71924100 @default.
• W2980234003 hasConceptScore W2980234003C90924648 @default.
• W2980234003 hasLocation W29802340031 @default.
• W2980234003 hasOpenAccess W2980234003 @default.
• W2980234003 hasPrimaryLocation W29802340031 @default.
• W2980234003 hasRelatedWork W1976402300 @default.
• W2980234003 hasRelatedWork W2066564017 @default.
• W2980234003 hasRelatedWork W2071549499 @default.
• W2980234003 hasRelatedWork W2134861285 @default.
• W2980234003 hasRelatedWork W2140395974 @default.
• W2980234003 hasRelatedWork W2154066874 @default.
• W2980234003 hasRelatedWork W2171771895 @default.
• W2980234003 hasRelatedWork W2199407694 @default.
• W2980234003 hasRelatedWork W2375500881 @default.
• W2980234003 hasRelatedWork W2389761994 @default.
• W2980234003 hasRelatedWork W2511310313 @default.
• W2980234003 hasRelatedWork W2560462604 @default.
• W2980234003 hasRelatedWork W2620328644 @default.
• W2980234003 hasRelatedWork W2907330471 @default.
• W2980234003 hasRelatedWork W2955678470 @default.
• W2980234003 hasRelatedWork W2959948243 @default.
• W2980234003 hasRelatedWork W2979365039 @default.
• W2980234003 hasRelatedWork W2979804808 @default.
• W2980234003 hasRelatedWork W3087270458 @default.
• W2980234003 hasRelatedWork W3112764266 @default.
• W2980234003 isParatext "false" @default.
• W2980234003 isRetracted "false" @default.
• W2980234003 magId "2980234003" @default.
• W2980234003 workType "article" @default.